A new digital medical device, called florio HAEMO, may support more personalized care and help people with hemophilia better plan daily activities and live their normal life, a study suggests. The device helps patients and clinicians monitor real-world, real-time data on treatment and clinical outcomes, including pain, bleeding, well-being, and…
Search results for:
Hemophilia News Today brought you coverage of the latest developments in research and advances in treatments for hemophilia in 2023. Here we’ve compiled a list of the top 10 most-read articles published on our site last year. We hope to continue being a resource for the hemophilia community…
Ixinity (trenonacog alfa; IB1001) is an approved replacement therapy designed to prevent or treat bleeding episodes in adults and children, ages 12 and older, with hemophilia B.
BioMarin Pharmaceuticals is moving forward with BMN 270, an experimental gene therapy for the treatment of hemophilia A, and is preparing new clinical trials expected to begin this year. The European Medicines Agency (EMA)’s Committee for Advanced Therapies (CAT) and its Committee for Medicinal Products for Human Use (CHMP) agreed that BMN 270…
In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE: The Hemophilia CHOICE Project Survey The podcasts feature a pediatric hematologist, Dr. Arash…
Shire has asked the U.S. Food and Drug Administration to grant Investigational New Drug status to its hemophilia A treatment SHP654. The gene therapy helps generate a clotting protein known as factor VIII that is missing or defective in hemophilia A. Shire said an FDA approval of its request will…
NovoSeven stops or slows bleeding in children with hemophilia but is associated with blood clotting, a study of hospital medical records indicates. The team that did the retrospective study said more risk-benefit studies of children’s use of NovoSeven are needed. NovoSeven is also known as recombinant activated factor VII – rFVIIa. The…
Switching to extended half-life (EHL) products has provided a reduction in the number of infusions and fewer bleeding events compared to standard treatments, particularly in hemophilia B, according to early real-world data from Europe. The study, “Real‐life experience in switching to new extended half‐life products…
Cyklokapron (tranexamic acid) is an approved hemophilia medication that's designed to control or prevent bleeding episodes in patients, and reduce the need for replacement therapy during and following a tooth extraction.